A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib

Laboratory abnormalities in patients with COVID-2019 infection

(2020) Giuseppe Lippi et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

(2020) William J. Sandborn et al.   GASTROENTEROLOGY

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

(2020) Peter Richardson et al.   LANCET

COVID-19: combining antiviral and anti-inflammatory treatments

(2020) Justin Stebbing et al.   LANCET INFECTIOUS DISEASES

The safety of baricitinib in patients with rheumatoid arthritis

(2020) Suguru Honda et al.   Expert Opinion On Drug Safety

Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase

(2020) Enriqueta Vallejo-Yagüe et al.   DRUG SAFETY

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

(2019) Anniina T. Virtanen et al.   BIODRUGS

Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials

(2019) Wenhui Xie et al.   ANNALS OF THE RHEUMATIC DISEASES

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

(2019) Katie Bechman et al.   RHEUMATOLOGY

Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors

(2019) Jun Dai et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

(2019) Peter C. Taylor et al.   Journal of Clinical Medicine

JAK inhibitors for the treatment of autoimmune and inflammatory diseases

(2019) Yvan Jamilloux et al.   AUTOIMMUNITY REVIEWS

Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

(2018) Ian C. Scott et al.   DRUG SAFETY

Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2018) Feng Huang et al.   BIODRUGS

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

(2018) Josef S. Smolen et al.   JOURNAL OF RHEUMATOLOGY

OUP accepted manuscript

(2018)   RHEUMATOLOGY

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

(2017) Daniella M. Schwartz et al.   NATURE REVIEWS DRUG DISCOVERY

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2013) Toshiyuki Sakaeda et al.   International Journal of Medical Sciences

Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis

(2012) Jessica Widdifield et al.   ARTHRITIS CARE & RESEARCH